Pioglitazone ameliorates high glucose induced desensitization of insulin receptor kinase in Rat 1 fibroblasts in culture

Biochem Biophys Res Commun. 1993 Dec 30;197(3):1078-82. doi: 10.1006/bbrc.1993.2588.

Abstract

A new oral agent, pioglitazone, increases insulin sensitivity by activating receptor kinase in insulin-resistant rats. To clarify the mechanism, we studied in vitro effects of glucose and pioglitazone on the insulin receptor function using Rat 1 fibroblasts which expressed human insulin receptors. Insulin receptor kinase activity was impaired by incubating cells for 4 days in the presence of 27mM D-glucose. The glucose effect was time- and dose-dependent and also specific for D-glucose, since D-raffinose incubation had no effect. Pioglitazone treatment did not have any effect on intact receptor kinase. However, exposure of both 27mM D-glucose and 0.1 microM pioglitazone to the cells completely prevented the glucose-induced impairment of insulin receptor kinase activity, suggesting that pioglitazone might reverse the processes which are critical for the glucose-induced desensitization of insulin receptor kinase.

MeSH terms

  • Animals
  • Cell Line
  • Enzyme Activation
  • Fibroblasts / drug effects
  • Fibroblasts / enzymology
  • Glucose / antagonists & inhibitors
  • Glucose / pharmacology*
  • Hypoglycemic Agents / pharmacology*
  • Insulin / metabolism
  • Kinetics
  • Phosphorylation
  • Pioglitazone
  • Protein-Tyrosine Kinases / metabolism
  • Rats
  • Receptor, Insulin / isolation & purification
  • Receptor, Insulin / metabolism*
  • Thiazoles / pharmacology*
  • Thiazolidinediones*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Thiazoles
  • Thiazolidinediones
  • Protein-Tyrosine Kinases
  • Receptor, Insulin
  • Glucose
  • Pioglitazone